Back

AI/ML-Assisted Computational Design and Immunoinformatics Evaluation of a Multi-Epitope Vaccine Targeting Podoplanin in Glioblastoma Multiforme

Anilkumar, G.; Saluja, R. S.; Mittal, A.; Shah, P. S.; Shah, S.; Kharkar, P.

2026-02-19 immunology
10.64898/2026.02.18.706629 bioRxiv
Show abstract

Glioblastoma Multiforme (GBM) is one of the most malignant forms of brain tumor in humans, with limited treatment options and poor overall survival rates. In the present study, we employed an in-silico workflow that integrated immunoinformatics and 3D structural modelling tools to design a multi-epitope vaccine against Podoplanin (PDPN), a transmembrane glycoprotein primarily involved in tumor invasion and metastasis. The differential expression of PDPN in tumor versus normal cells was investigated using transcriptomics datasets. Once the overexpression was confirmed, it was designated as a Tumor-Associated Antigen (TAA). B-cell, CTL, and HTL epitopes were predicted and screened for antigenicity, non-allergenicity, and non-toxicity. Selected epitopes were linked with appropriate adjuvant and linker sequences to construct a vaccine candidate. Codon optimization and in silico cloning was conducted to evaluate the constructs expression in a mammalian expression vector. The 3D structure of the vaccine candidate was modelled, refined, and validated before molecular docking with immune receptors and immune simulation studies. The results indicated that proposed polypeptide, RasIC-01v, could be a potential vaccine candidate for highly vigorous and dangerous cancer like GBM. Further experimental and immunological validations would be required to validate the commercial feasibility and development of RasIC-01v. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=116 SRC="FIGDIR/small/706629v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@7485b1org.highwire.dtl.DTLVardef@1f551c1org.highwire.dtl.DTLVardef@ca871eorg.highwire.dtl.DTLVardef@6cf53d_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Journal of Biomolecular Structure and Dynamics
43 papers in training set
Top 0.1%
10.4%
2
Antibody Therapeutics
16 papers in training set
Top 0.1%
6.6%
3
Vaccines
196 papers in training set
Top 0.4%
5.0%
4
Frontiers in Immunology
586 papers in training set
Top 1%
5.0%
5
Computational and Structural Biotechnology Journal
216 papers in training set
Top 1.0%
4.4%
6
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.1%
4.1%
7
PLOS ONE
4510 papers in training set
Top 38%
3.7%
8
Scientific Reports
3102 papers in training set
Top 34%
3.7%
9
Journal of Chemical Information and Modeling
207 papers in training set
Top 2%
2.4%
10
International Journal of Biological Macromolecules
65 papers in training set
Top 1.0%
2.4%
11
Computers in Biology and Medicine
120 papers in training set
Top 1%
2.1%
12
Infection, Genetics and Evolution
43 papers in training set
Top 0.2%
2.1%
50% of probability mass above
13
Molecular Pharmaceutics
16 papers in training set
Top 0.2%
1.7%
14
Biology Methods and Protocols
53 papers in training set
Top 1%
1.5%
15
Briefings in Bioinformatics
326 papers in training set
Top 4%
1.5%
16
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.5%
17
Pharmaceuticals
33 papers in training set
Top 1.0%
1.3%
18
Frontiers in Plant Science
240 papers in training set
Top 4%
1.1%
19
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 2%
1.1%
20
Biochemistry and Biophysics Reports
28 papers in training set
Top 1.0%
1.0%
21
Frontiers in Molecular Biosciences
100 papers in training set
Top 3%
1.0%
22
International Journal of Molecular Sciences
453 papers in training set
Top 12%
0.9%
23
iScience
1063 papers in training set
Top 26%
0.9%
24
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
25
Cellular & Molecular Immunology
14 papers in training set
Top 2%
0.8%
26
Nanoscale Advances
13 papers in training set
Top 0.5%
0.8%
27
PeerJ
261 papers in training set
Top 15%
0.7%
28
Emerging Microbes & Infections
74 papers in training set
Top 2%
0.7%
29
Cell Reports
1338 papers in training set
Top 33%
0.7%
30
eLife
5422 papers in training set
Top 60%
0.7%